CEVI logo

CellaVision AB (publ) Stock Price

OM:CEVI Community·SEK 4.2b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

CEVI Share Price Performance

SEK 177.20
-111.30 (-38.58%)
21.2% undervalued intrinsic discount
SEK 225.00
Fair Value
SEK 177.20
-111.30 (-38.58%)
22.3% undervalued intrinsic discount
SEK 228.00
Fair Value
Price SEK 177.20
AnalystConsensusTarget SEK 228.00

CEVI Community Narratives

AnalystConsensusTarget·
Fair Value SEK 225 18.8% undervalued intrinsic discount

Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative

Recent CEVI News & Updates

Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Aug 22
Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

Here's What Analysts Are Forecasting For CellaVision AB (publ) (STO:CEVI) After Its Second-Quarter Results

Jul 23
Here's What Analysts Are Forecasting For CellaVision AB (publ) (STO:CEVI) After Its Second-Quarter Results

There's Reason For Concern Over CellaVision AB (publ)'s (STO:CEVI) Massive 29% Price Jump

May 04
There's Reason For Concern Over CellaVision AB (publ)'s (STO:CEVI) Massive 29% Price Jump

Is There Now An Opportunity In CellaVision AB (publ) (STO:CEVI)?

Apr 30
Is There Now An Opportunity In CellaVision AB (publ) (STO:CEVI)?

CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50

Apr 03
CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.50

CellaVision AB (publ) Key Details

SEK 751.5m

Revenue

SEK 234.2m

Cost of Revenue

SEK 517.2m

Gross Profit

SEK 366.1m

Other Expenses

SEK 151.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 06, 2025
Earnings per share (EPS)
6.34
Gross Margin
68.83%
Net Profit Margin
20.12%
Debt/Equity Ratio
3.7%

CellaVision AB (publ) Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet and undervalued.

0 Risks
4 Rewards

About CEVI

Founded
1994
Employees
229
CEO
Simon Ostergaard
WebsiteView website
www.cellavision.com

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Swedish Market Performance

  • 7 Days: -1.1%
  • 3 Months: 1.2%
  • 1 Year: -1.3%
  • Year to Date: 2.0%
Over the last 7 days, the market has dropped 1.1%, driven by a pullback of 1.7% in the Industrials sector. Although the market performance has been flat over the past year. Looking forward, earnings are forecast to grow by 16% annually. Market details ›